Celyad

Kempen is pleased to announce that it acted as Co-Manager in Celyad’s capital increase via accelerated bookbuild offering of c. USD 20 million (c. €18.2 million)

• The transaction of 2,000,000 ordinary shares, comprised of 1,717,391 ADSs and 282,609 ordinary shares. Each ADS represents the right to receive one ordinary share
• The offer price was set at USD 10.00 per ADS and at €9.08 per ordinary share
• Gross proceeds amount to c. USD 20 million (c. €18.2 million) and will be used, among others, to advance the development of CYAD-01, CYAD-101, CYAD-02, additional product candidates in its CYAD-200 series, and for general corporate purposes
• In line with last year’s raise, the orderbook was kept open for 24h allowing European, Israeli and US investors to join the transaction
• Kempen’s added value in Celyad’s global offering originates from outreach to both European and Israeli specialist investors
• This transaction builds on the long-standing relationship between Celyad and Kempen, which started with its Euronext IPO in 2013. This successful offering marks Kempen’s fifth US transaction in underwriting capacity since obtaining its US license one year ago. Over the past twelve months, Kempen was involved in fourteen life sciences ECM transactions with an aggregate deal value exceeding €1.7 billion

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD.

Over the past year, Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: Co-Manager in the USD 582 million NASDAQ Initial Public Offering of Genmab, Joint Bookrunner in the €116 million secondary sale of Fagron shares by Waterland and Baltisse, Joint Bookrunner in the €48.7 million rights issue by Transgene, Joint Bookrunner in the SEK 727 million capital increase by Oncopeptides, Co-Manager in the USD 84 million NASDAQ Initial Public Offering of HOOKIPA Pharma, Sole Block Placing Agent of c. USD 130 million argenx shares, Joint Global Coordinator and Joint Bookrunner in the €27.5 million Initial Public Offering of Sequana Medical, Joint Bookrunner in the NOK 222 million capital increase by Nordic Nanovector, Joint Bookrunner in the €55.5 million capital increase by Biocartis, Sole Financial Adviser in the sale of Medsen Pharmacies and compounding pharmacy Ceban, Joint Bookrunner in the €31.2 million capital increase by Kiadis, Co-Manager in the USD 301 million capital increase by argenx, Co-Manager in the USD 345 million capital increase by Galapagos and Adviser in the USD 104 million capital increase by ProQR.